Seng-Ho Jeon, CEO of Daewoong Pharmaceutical, remarked, "Last year, Daewoong Pharmaceutical declared the '2030 Global Formulation No.1' vision and has since been dedicated to new administration route technology, specifically microneedles
Currently, retatrutide is in phase 3 clinical trials to determine its long-term safety and efficacy for weight loss in obese and overweight individuals, knee osteoarthritis, and obstructive sleep apnea
and permitting flexibility with food choices and occasional portion-controlled treats rather than severe restriction
Weight regain after stopping is documented and common
Conflating failed pharmacology with failed biology risks permanently sidelining therapeutically valuable systems, while indiscriminately resurrecting abandoned targets without rigorous criteria risks repeating historical mistakes
Integration with therapy and lifestyle interventions